Compare Citius Pharmaceuticals Inc (CTXR) vs EPAM Systems Inc (EPAM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs EPAM Systems Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while EPAM Systems Inc trades at $112.92 (market cap $5.87B). The key difference: EPAM Systems Inc is far larger — about 431× Citius Pharmaceuticals Inc's market cap, and EPAM Systems Inc is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and EPAM Systems Inc for 37 Days on average.
| CTXR | EPAM | |
|---|---|---|
Market Cap | $13.62M | $5.87B |
Volume | 132,438 | 847,420 |
Sector | Health | Technology |
52-Week High | $1.82 | $221.40 |
52-Week Low | $0.48 | $76.04 |
Typical Hold Time | 17 Days | 37 Days |
Enterprise Value | $3.79M | $5.24B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
EPAM Systems trades at $113.24, up 4.54% today, reflecting strong momentum. The stock shows a bullish technical trend, trading near resistance at $115. Fundamentally, EPAM reported Q2 2026 EPS of $3.38, beating estimates, with revenue reaching $5.46B in 2025. Recent news highlights a partnership with Wiz for cloud security and activist investor Engine Capital urging share buybacks, signaling confidence in undervaluation.
The outlook is positive, supported by a consensus price target of $119 and strong analyst buy ratings (59.46%). However, risks include slower North American growth and AI disruption to legacy services. The stock presents a value opportunity with a P/E of 15.45, but investors should monitor execution on AI-native revenue growth and margin sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About EPAM Systems Inc
EPAM Systems Inc provides software product development and digital platform engineering services to clients located around the world. The company services include Software Product Development, Custom Application Development, Application Testing, Enterprise Application Platforms, Application Maintenance, and Support and Infrastructure Management. The company focuses on innovative and scalable software solutions. The company uses industry standard and custom developed technology, tools, and platforms to deliver results to handle business challenges. The company primarily offers its solutions in the following industries: financial services, travel and consumer, software and hi-tech, life sciences and healthcare. The majority of revenue is generated from North American clients.
Read more on EPAM →
